biomarkers

Is Alkaline Phosphatase A Bio-Marker To Predict PSA Decline And Clinical Benefit From Abiraterone Acetate in Bone Metastatic Castration Resistant Prostate Cancer

Again and again I have mentioned the huge need we have for the development of reliable bio-markers. Reliable bio-markers will allow us to know which men will respond positively to a treatment (also those who will not) and when a treatment is still effective (also when it no longer is effective). These biomarkers really don’t exist, so a lot of clinical decision-making is based upon the experience and gut feeling of our doctors. This type of decision-making is not adequate in today’s world of multiple treatment options, especially when many of the treatments can foster resistance to other available treatments. [...]

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to decide at what point additional treatment would most benefit a man with recurrent prostate cancer. To accomplish this goal researchers reviewed the long-term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. The study was large, including [...]

From Active Surveillance to Metastatic Prostate Cancer – Know The Risks As You Decide

Historically, too many men were haphazardly treated for prostate cancer. Happily, the incidents of over treatment have been declining and the general acceptance of Active Surveillance has emerged as the preferred management strategy for men with very low–risk prostate cancer. However, There is still too few high-quality comparative effectiveness studies evaluating the incremental risks associated with or active surveillance. In a prospective study published in the Journal of Urology, researchers reported the risk men face of developing metastatic disease. They evaluated a large, mature, active surveillance cohort. It was reported that, at median follow-up of 6 years, 3.1% of men [...]

An Independent Prognostic Tool For Men With Metastatic Castrate Resistant Prostate Cancer Taking The Newer Drugs

We have a number of newer hormone pathway drugs now available to treat men with metastatic castrate resistant prostate cancer (mCRPC). Researchers have shown that prostate specific antigen (PSA) response can be used as a pharmaco-dynamic end-point that may help identify men with early resistance to these new drugs. They found that there is clinical significance of an early PSA response (EPR) during therapy with enzalutamide, abiraterone acetate (AA) and orteronel in mCRPC. The researchers evaluated PSA values at baseline and then 28 days after beginning treatment in men who were recruited from other clinical trials. They defined EPR as a decline [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー